Wall Street expects Thermo Fisher Scientific to report Q3 2026 revenue of $11.93 billion and adjusted EPS of $6.40, with the stock currently trading at $679.37 compared to an average analyst price target of $682.12. Investors are primarily focused on the company’s organic revenue growth, which management and analysts anticipate will settle at approximately 4% for the quarter.
This growth trajectory follows a momentum-building second quarter characterized by a recovery in academic and government funding and a return to growth in the Chinese market. Recent product launches in the Life Sciences Solutions segment and strong bioproduction orders suggest that the company is effectively navigating the post-pandemic biotech funding environment, though investors are watching for continued margin expansion in a high-interest-rate landscape.